Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125222 · ClinicalTrials.gov registry record · Phase 2
Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT07125222 is a Phase 2 study that has not yet begun recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 24 participants.
The verdict
NCT07125222, a Phase 2 study, has not yet begun recruiting, sponsored by Weill Medical College of Cornell University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
Interventions
- DRUG Gocovri (extended-release amantidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-09 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07125222
The ClinicalTrials.gov registry entry for NCT07125222 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gocovri (extended-release amantidine) is the first listed.
NCT07125222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07125222 about?
NCT07125222 is a clinical study titled "Use of Gocovri to Improve Disability Due to Radiation Encephalopathy". A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.
What is the current status of trial NCT07125222?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2025-09. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07125222?
The interventions under investigation include: Gocovri (extended-release amantidine) (DRUG).
Who is sponsoring clinical trial NCT07125222?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.